To help clients more efficiently access the cost savings of biosimilars, MedBen Rx is introducing an advance notice model. Rather than requiring approval each time a new biosimilar becomes available, this proactive approach automatically adds new biosimilars to your plan’s formulary after notice is provided.
Under this new model, clients will receive a 60-day advance notice before a biosimilar is added to their formulary. This ensures full transparency while simplifying the approval process. Clients who prefer not to participate may choose to opt out of the biosimilar program, though the model requires a full opt-in or opt-out approach – individual product selections are not available.
This move reflects the rapid growth of biosimilars entering the market. With dozens of new products expected over the next few years, this streamlined process allows MedBen Rx clients to take advantage of available savings more quickly, without the delays that can come with case-by-case approvals.
MedBen Rx already offers biosimilars for Humira and Stelara, with a Prolia biosimilar coming soon. Clients using these biosimilars through MedBen Rx are realizing substantial savings – nearly 90% on Humira and up to 95% on Stelara compared to the brand-name versions.
To learn more about the biosimilar notice model, MedBen Rx clients can contact their Account Management team. If you’re not currently a MedBen Rx client, reach out to your broker or MedBen Rx Marketing to see how this program can help lower your pharmacy costs while maintaining the same high standards of care.